New York City, NY - October 21, 2025 - Waypoint Bio, a biotech company pioneering next-generation cell therapies for solid tumors, is excited to welcome Patrick Kaifosh, Ph.D., as its new Chief Technology Officer. Dr. Kaifosh brings a track record of innovation in neurotechnology and artificial intelligence, having previously led research as Director of Research Science at Meta and co-founded CTRL-Labs, which was acquired by Meta in 2019.

At Waypoint, Dr. Kaifosh will drive the advancement of its AI-powered biotechnology platform, accelerating drug discovery efforts and expanding computational and automation capabilities. His leadership will strengthen integration across machine learning, robotics, and spatial biology, with an eye toward developing innovative T cell therapies for cancer treatment.

Waypoint Bio leverages artificial intelligence and spatial biology to engineer next-generation T cell therapies that thrive in the solid tumor microenvironment. The company is focused on developing in vivo CAR T cell therapies, the first of which will enter clinical trials in 2026.

“Patrick’s knowledge at the intersection of biology and machine learning represents exactly the kind of visionary technical leader we need as we scale our platform,” said Xinchen Wang, Co-Founder and CEO of Waypoint Bio. “His expertise building AI systems that decode complex biological signals, combined with his deep neuroscience background, makes him uniquely qualified to help us unlock the full potential of spatial biology for drug discovery. This is part of our ongoing commitment to building a team that can fundamentally transform how we engineer cell therapies.”

At Meta, Dr. Kaifosh led groundbreaking work developing non-invasive neural interfaces that translate human neuromotor signals into digital commands using advanced machine learning models. He played a pivotal role at Meta in neuromotor interface research and commercialization of CTRL-Labs’ technology. His team’s research, recently published in Nature, demonstrated the first high-bandwidth neuromotor interface capable of working across populations without per-person calibration–a feat requiring sophisticated AI architectures trained on data from thousands of participants.

Dr. Kaifosh co-founded CTRL-Labs alongside Thomas Reardon (creator of Internet Explorer), and served as Chief Scientific Officer. The company developed a non-invasive wristband for sensing and interpreting muscle activity – technology now featured in Meta’s Ray-Ban Display product. Dr. Kaifosh holds a Ph.D. in Neurobiology and Behavior from Columbia University.

“I’m thrilled to be joining Waypoint at a major inflection point,” said Dr. Kaifosh. “The team has built a best-in-class spatial biology platform for discovery and optimization of cell therapies. Having validated the platform with a highly promising lead program in gastric cancer, we’re now ready to extend its reach across a broad spectrum of diseases.”

“Waypoint Bio has positioned itself at the intersection of three fields - spatial biology, cell therapies, and AI - each undergoing an explosive transformation,” Dr. Kaifosh continued. “By combining rich datasets with cutting edge machine learning to optimize cellular engineering, we have the opportunity to develop more effective therapies for patients.”

The company was named among GEN’s Top 10 Spatial Biology Companies of 2024 and recently joined JLABS @ NYC under Johnson & Johnson Innovation. With two new collaborations underway, $14.5M in seed financing, and awards as a Golden Ticket winner by Bristol Myers Squibb and Otsuka, these milestones underscore the momentum behind Waypoint’s mission as it advances toward in vivo CAR-T development.

About Waypoint Bio
Waypoint Bio is a biotechnology company pioneering novel cell therapies for solid tumors using its proprietary spatial pooled screening technology and lab-in-the-loop approach. The company, which emerged from stealth in 2024, has raised $14.5 million in funding from leading biotech and tech investors and assembled a scientific advisory board for drug R&D and cancer experts. While the company is currently focused on designing novel cell therapies for solid tumors, its technology has the potential for more drug discovery applications, including Treg therapies for autoimmune diseases. Waypoint Bio is headquartered in New York City. Learn more at waypointbio.com.

‍